Bristol-Myers and Vedanta to develop new Opdivo combo

New York’s Bristol-Myers Squibb (NYSE: BMY) has agreed terms for a collaboration with Vedanta Biosciences, an affiliate of London-listed PureTech Health (LSE: PRTC).

The clinical trial collaboration will test a combination of Bristol-Myers’ blockbuster checkpoint inhibitor Opdivo (nivolumab) and Vedanta’s VE800, in people with advanced or metastatic cancers.

VE800 has been shown in preclinical models to induce CD8+ T cells, potentiate the immune system’s attack of tumor cells, and significantly amplify the effects of anti-PD-1 therapy.